Wordt geladen...
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-r...
Bewaard in:
| Gepubliceerd in: | Lancet Oncol |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5702534/ https://ncbi.nlm.nih.gov/pubmed/27924752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30406-5 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|